Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 14/20 | 0.78 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7963672 | 0.89 | CMA1 (0.67) | CMA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6115259 | 0.88 | CMA1 (1.00) | CMA1CTSGCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7960258 | 0.83 | CMA1 (1.00) | CMA1CTSGCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL1847165 | 0.83 | CMA1 (0.80) | CMA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL18900941 | 0.82 | CMA1 (0.79) | CMA1CTSGCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7963656 | 0.77 | POLB (0.48) | CMA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7959067 | 0.75 | CMA1 (0.85) | CMA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7951286 | 0.75 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL6115315 | 0.74 | CMA1 (0.67) | CMA1CTSGCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7961042 | 0.74 | CMA1 (0.83) | CMA1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323991-B1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010019417-A2 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129863-A1 | CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885CTSG 14/4885CYP1A2 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.